Gland Pharma announced robust Q3 FY26 results, with revenue increasing by 22% year-over-year. Adjusted PAT also saw a significant rise of 37%. This growth was attributed to consistent execution across key markets and improved operational efficiencies. The company remains optimistic about sustaining this momentum through new product launches and CDMO contract ramp-ups. Key markets like the US and Europe showed double-digit growth.
Financial Performance
Gland Pharma reported a strong financial performance for Q3 FY26. Revenue from operations reached ₹16,954 million, a 22% increase compared to Q3 FY25 (₹13,841 million). Adjusted PAT also experienced substantial growth, rising by 37% year-over-year.
Key Growth Drivers
The company’s performance was driven by several factors, including:
- Consistent execution across key markets, particularly in the US and Europe.
- Steady improvement in margins.
- New product launches and CDMO contract ramp-ups.
Segmental Performance
Base Business (Gland): Revenue increased by 16% year-over-year. Adjusted EBITDA increased by 11% year-over-year, and adjusted PAT increased by 14% year-over-year.
Cenexi: Revenue increased by 39% year-over-year. Fontenay Facility: New high-capacity ampoule line is being added, with a capacity of 30 million by 2027.
R&D Investment
The company increased its investment in research and development, with total R&D expenses reaching ₹650 million in Q3 FY26, representing 5.4% of revenue. This compares to ₹437 million in Q3 FY25.
New Product Launches and Filings
Gland Pharma launched nine new molecules in the US during the quarter. The company also filed nine ANDAs and received approval for four ANDAs in Q3 FY26.
Source: BSE
